Privia Health Group, Inc. (PRVA) Financial Statements
Privia Health Group, Inc. (PRVA) reported trailing twelve-month revenue of $2.4B (up 24.1% year on year) and net income of $28.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $131.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRVAPrivia Health Group, Inc.Follow PRVA — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- 106.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.97 | 1.36 | 1.66 | 1.74 | 2.12 | 2.36 | |
| Gross profit | 0.04 | 0.11 | 0.13 | 0.14 | 0.17 | 0.19 | |
| Operating income | -0.22 | -0.02 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Pre-tax income | -0.22 | -0.02 | 0.03 | 0.03 | 0.04 | 0.06 | |
| Income tax | -0.03 | -0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Net income | -0.19 | -0.01 | 0.02 | 0.01 | 0.02 | 0.03 | |
| Diluted EPS ($) | -1.83 | -0.08 | 0.19 | 0.11 | 0.18 | 0.21 | |
| Diluted shares (bn) | 0.103 | 0.111 | 0.125 | 0.126 | 0.129 | — |
USD billions · SEC XBRL
Privia Health Group, Inc. — questions
- What is Privia Health Group, Inc.'s revenue?
- $2.4B over the twelve months to 2026-06-30, up 24.1% year on year, from its 10-Q and 10-K filings.
- What is Privia Health Group, Inc.'s net income?
- $28.1M over the twelve months to 2026-06-30.
- What is Privia Health Group, Inc.'s free cash flow?
- $131.1M over the twelve months to 2026-06-30.
- What are Privia Health Group, Inc.'s diluted earnings per share?
- $0.21 over the twelve months to 2026-06-30.
Every figure on this page comes from Privia Health Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.